Charles River Laboratories (CRL) Stock
Global lab services provider for drug development. Here's the price, business snapshot, and what's worth knowing about Charles River Laboratories in October 2026.
Charles River Laboratories (CRL) provides a wide range of research models, preclinical and clinical laboratory services to pharmaceutical, biotechnology and academic customers. The firm supports drug discovery and development with animal models, safety assessment, biologics testing and specialised lab services that help clients progress candidates from discovery to market. Outsourcing trends, rising R&D spending by biopharma, and growth in biologics and cell & gene therapies are structural drivers often cited by investors. CRL’s scale and global footprint can offer cross-border service continuity, though earnings are sensitive to industry R&D cycles, regulatory changes and ethical or reputational issues around animal research. The company’s mid-cap market capitalisation (about $9.27bn) places it among larger contract research providers but competition and integration of acquisitions are ongoing considerations. This summary is educational only; it isn’t investment advice. Investors should assess their own goals, risk tolerance and check up-to-date company filings and market data before acting.
Why You’ll Want to Watch This Stock
Outsourcing Tailwinds
Pharmaceutical firms increasingly outsource specialist testing and models, which can support demand for CRL’s services — though demand may fluctuate with R&D budgets.
Global Service Footprint
A broad international network helps serve multinational clients and diversify revenue, but global regulation and integration risks persist.
Biologics & Innovation
Growth in biologics, cell and gene therapies can create higher-value testing needs that favour specialists, although technological and regulatory shifts bring uncertainty.
